Evidence map›Paper›PMID 42366580›Full record

ArticleMuscle & nerve2026

At-Home Versus in-Clinic Vital Capacity Measurement: Insights From the HEALEY ALS Platform Trial.

Eric A Macklin, James D Berry, Brittney A Harkey, Lindsay Heyd, Marianne Chase, Hong Yu, Alexander V Sherman, Derek Dagostino, Gale Kittle, Meghan Hall and 13 more

Abstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Muscle & nerve, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Eric A MacklinSean M. Healey and AMG Center for ALS & the Neurological Clinical Research Institute, Massachusetts General Hospital, Boston, Massachusetts, USA.
James D BerrySean M. Healey and AMG Center for ALS & the Neurological Clinical Research Institute, Massachusetts General Hospital, Boston, Massachusetts, USA.
Brittney A HarkeySean M. Healey and AMG Center for ALS & the Neurological Clinical Research Institute, Massachusetts General Hospital, Boston, Massachusetts, USA.
Lindsay HeydSean M. Healey and AMG Center for ALS & the Neurological Clinical Research Institute, Massachusetts General Hospital, Boston, Massachusetts, USA.
Marianne ChaseSean M. Healey and AMG Center for ALS & the Neurological Clinical Research Institute, Massachusetts General Hospital, Boston, Massachusetts, USA.
Hong YuSean M. Healey and AMG Center for ALS & the Neurological Clinical Research Institute, Massachusetts General Hospital, Boston, Massachusetts, USA.
Alexander V ShermanSean M. Healey and AMG Center for ALS & the Neurological Clinical Research Institute, Massachusetts General Hospital, Boston, Massachusetts, USA.
Derek DagostinoSean M. Healey and AMG Center for ALS & the Neurological Clinical Research Institute, Massachusetts General Hospital, Boston, Massachusetts, USA.
Gale KittleBarrow Neurological Institute, Phoenix, Arizona, USA.
Meghan HallBarrow Neurological Institute, Phoenix, Arizona, USA.
Mariah R ConnollyBarrow Neurological Institute, Phoenix, Arizona, USA.
Kristin DrakeSean M. Healey and AMG Center for ALS & the Neurological Clinical Research Institute, Massachusetts General Hospital, Boston, Massachusetts, USA.
Elisa GiacomelliSean M. Healey and AMG Center for ALS & the Neurological Clinical Research Institute, Massachusetts General Hospital, Boston, Massachusetts, USA.
Erica SciroccoSean M. Healey and AMG Center for ALS & the Neurological Clinical Research Institute, Massachusetts General Hospital, Boston, Massachusetts, USA.ORCID https://orcid.org/0009-0002-9427-1452
Saloni SharmaSean M. Healey and AMG Center for ALS & the Neurological Clinical Research Institute, Massachusetts General Hospital, Boston, Massachusetts, USA.
Suma BabuSean M. Healey and AMG Center for ALS & the Neurological Clinical Research Institute, Massachusetts General Hospital, Boston, Massachusetts, USA.
Michael BenatarDepartment of Neurology and the ALS Center, Miller School of Medicine, University of Miami, Miami, Florida, USA.
Zachary SimmonsPenn State Health Milton S. Hershey Medical Center, Hershey, Pennsylvania, USA.ORCID https://orcid.org/0000-0001-8574-5332
Eufrosina YoungUpstate Medical University, Syracuse, New York, USA.
Merit E CudkowiczSean M. Healey and AMG Center for ALS & the Neurological Clinical Research Institute, Massachusetts General Hospital, Boston, Massachusetts, USA.
Jeremy ShefnerBarrow Neurological Institute, Phoenix, Arizona, USA.
Sabrina PaganoniSean M. Healey and AMG Center for ALS & the Neurological Clinical Research Institute, Massachusetts General Hospital, Boston, Massachusetts, USA.ORCID https://orcid.org/0000-0003-0505-1168
HEALEY ALS Platform Trial Study Group

Funding

ALS AssociationALS Finding a CureALS ONEMuscular Dystrophy Association MDA 1313867Tackle ALSThe AMG Charitable FoundationThe Arthur M. Blank Family Foundation
6 · The paper itself

Abstract

INTRODUCTION/

aimsRespiratory weakness, typically monitored as vital capacity (VC), is a central feature of amyotrophic lateral sclerosis (ALS). VC is increasingly measured remotely in participants' homes, although in-clinic assessment remains the standard. We tested concordance between at-home and in-clinic VC to determine trial eligibility, track progression, and predict survival in a large ALS trial.

methodsAt-home and in-clinic VC were assessed at baseline and approximately every 8 weeks for a year in the first four regimens of the HEALEY ALS Platform Trial. At-home assessments were coached via live videoconference and centrally reviewed. VC measurements, expressed as percent of predicted normal (%PN), were compared cross-sectionally, longitudinally, and for predicting survival time. Data from 233 participants with 3-8 paired at-home and in-clinic VC assessments completed < 14 days apart were analyzed.

resultsAt-home and in-clinic VC were well correlated (Lin's r DISCUSSION: At-home and in-clinic VC were well correlated cross-sectionally. At-home VC performed well tracking longitudinal change and predicting survival. The reduced participant burden of assessment and concordance with in-clinic measurement support use of at-home monitoring of VC.

Indexed as

Amyotrophic Lateral SclerosisAgedCross-Sectional StudiesDisease ProgressionFemaleHumansLongitudinal StudiesMaleMiddle AgedVital Capacityamyotrophic lateral sclerosisremote patient monitoringspirometryvalidation studies as topic

Identifiers

PMID42366580
PMCPMC13471965

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.